Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity

被引:13
|
作者
Rosenblat, Mira [1 ]
Volkova, Nina [1 ]
Aviram, Michael [1 ]
机构
[1] Technion Fac Med, Lipid Res Lab, Rappaport Family Inst Res Med Sci, Rambam Med Ctr, IL-31096 Haifa, Israel
关键词
Paraoxonase1; macrophages; HDL; cholesterol metabolism; oxidation; DENSITY-LIPOPROTEIN OXIDATION; SERUM PARAOXONASE; CHOLESTEROL-BIOSYNTHESIS; LIPID PEROXIDES; CORONARY; BINDING; CELLS;
D O I
10.1002/biof.188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We analyzed, for the first time, the effects of recombinant PON1 (rePON1) intraperitoneal injection to C57BL/6 mice on their HDL and macrophage antiatherogenic properties. Thioglycolate-treated mice were injected with either saline (Control), or rePON1 (50 mu g/mouse), and 20 H post injection, their blood samples and peritoneal macrophages (MPM) were collected. A significant increase in serum and HDL-PON1 arylesterase and lactonase activities was noted. Similarly, a significant increment, by 3.8 and 2.8 fold, in MPM-PON1 arylesterase and lactonase activities, respectively, as compared to the activities in control MPM was observed. The HDL from rePON1-injected mice was resistant to oxidation by copper ions as compared to control HDL. Furthermore, enrichment of the mouse HDL with rePON1 increased its ability to induce cholesterol efflux from J774A.1 macrophage cell line, and to inhibit macrophage-mediated LDL oxidation. In MPM from rePON1-injected mice vs. control MPM, there was a significant reduction in cholesterol mass, by 42%, in association with inhibition in cellular cholesterol biosynthesis rate, by 33%, and with significant stimulation, by 65%, of human HDL-mediated cholesterol efflux from the cells. We conclude that rePON1 injection to mice improved the mice HDL and MPM antiatherogenic properties, and these effects could probably lead to attenuation of atherosclerosis development.
引用
收藏
页码:462 / 467
页数:6
相关论文
共 50 条
  • [21] Paraoxonase 1 (PON1) status and substrate hydrolysis
    Richter, Rebecca J.
    Jarvik, Gail P.
    Furlong, Clement E.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 235 (01) : 1 - 9
  • [22] Paraoxonase 1 (PON1) is present in postprandial chylomicrons
    Fuhrman, B
    Volkova, N
    Aviram, M
    ATHEROSCLEROSIS, 2005, 180 (01) : 55 - 61
  • [23] Serum paraoxonase 1 (PON1) measurement: an update
    Jose J Ceron
    Fernando Tecles
    Asta Tvarijonaviciute
    BMC Veterinary Research, 10
  • [24] Paraoxonase 1 (PON1) polymorphisms and risk for migraine
    Garcia-Martin, Elena
    Martinez, Carmen
    Serrador, Mercedes
    Alonso-Navarro, Hortensia
    Navacerrada, Francisco
    Agundez, Jose A. G.
    Javier Jimenez-Jimenez, Felix
    JOURNAL OF NEUROLOGY, 2010, 257 (09) : 1482 - 1485
  • [25] Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter: A possible role for lysophosphatidylcholine
    Rosenblat, M
    Shih, D
    Vaya, J
    Aviram, M
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 40 - 40
  • [26] Functional genomics of the paraoxonase (PON1) polymorphisms
    Cole, TB
    Jarvik, GP
    Richter, RJ
    Jampsa, RL
    Carlson, CS
    Rieder, MJ
    Nickerson, DA
    Shih, DM
    Lusis, AJ
    Costa, LG
    Furlong, CE
    FASEB JOURNAL, 2003, 17 (04): : A158 - A158
  • [27] The active site of human paraoxonase (PON1)
    Josse, D
    Lockridge, O
    Xie, WH
    Bartels, F
    Schopfer, LM
    Masson, P
    JOURNAL OF APPLIED TOXICOLOGY, 2001, 21 : S7 - S11
  • [28] HDL-ASSOCIATED PARAOXONASE 1 (PON1) HYDROLYZING ACTIVITY AGAINST MACROPHAGE OXIDIZED LIPIDS PROTECTS AGAINST MACROPHAGE FOAM CELL FORMATION AND ATHEROGENESIS
    Aviram, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 47 - 47
  • [29] Polymorphisms in the human paraoxonase (PON1) promoter
    Brophy, VH
    Hastings, MD
    Clendenning, JB
    Richter, RJ
    Jarvik, GP
    Furlong, CE
    PHARMACOGENETICS, 2001, 11 (01): : 77 - 84
  • [30] Human paraoxonase (PON1) polymorphisms in Taiwanese
    Li, WF
    Chung, MC
    Chuang, HY
    Chang, LW
    DRUG METABOLISM REVIEWS, 2003, 35 : 66 - 66